6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 6 of 6 clinical reviews.
A detailed head-to-head comparison of flibanserin (Addyi) and bremelanotide (Vyleesi) across special populations including perimenopausal women, cancer survivors, women with cardiovascular risk, and those considering a switch between therapies.
A clinical comparison of Addyi (flibanserin) and Vyleesi (bremelanotide) for hypoactive sexual desire disorder, including mechanism, trial data, switching rationale, combination therapy risks, and prescribing guidance.
A head-to-head clinical comparison of flibanserin (Addyi) and bremelanotide (Vyleesi) for hypoactive sexual desire disorder, covering trial data, durability of effect, switching criteria, and real-world outcomes.
A clinician-reviewed comparison of Addyi (flibanserin) and Vyleesi (bremelanotide) for hypoactive sexual desire disorder, covering trial data, real-world outcomes, side-effect profiles, and switching guidance.
A head-to-head clinical comparison of flibanserin (Addyi) and bremelanotide (Vyleesi) covering titration schedules, tolerability profiles, and guidance on switching, reviewed by the HealthRX medical team.
Flibanserin (Addyi) and bremelanotide (Vyleesi) treat HSDD through different mechanisms. When one fails, the other may succeed. Learn the clinical criteria for switching, the trial data behind each drug, and the step-by-step protocol HealthRX clinicians use.